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S U M M A R Y
Objectives: To describe the distribution of vaccine and non-vaccine pneumococcal serotypes from adult
patients for different clinical scenarios, after the introduction of the 13-valent pneumococcal conjugate
vaccine (PCV-13) for children.
Methods: This was a prospective study of pneumococcal infections in adult patients (January 2010 to
April 2014) in Hospital Son Lla`tzer, Mallorca (Spain). Two different periods of time were compared, the
ﬁrst before (ﬁrst period) and the second after (second period) the introduction of PCV-13. Information
related to clinical characteristics, outcomes of infection, pneumococcal serotypes, and antibiotic
susceptibility was collected.
Results: We studied 407 episodes (371 patients), 201 in the ﬁrst period and 206 in the second period. The
majority of patients were male; the median patient age was 68 (range 15–99) years. Infections due to
PCV-13 serotypes decreased from 59.7% to 47.6% (p = 0.014), mainly serotypes 3, 7, 18C, 19F, and 23F. In
the second period, PCV-13 serotypes were the cause of pneumonia in 58.2% of cases and in 40.8% of
invasive infections, but these serotypes were not related with any outcome variable. No differences in
hospital or intensive care unit admission, severity, or mortality were observed between the two periods.
Susceptibility to penicillin (98.2% vs. 95.1%, p = 0.03) and amoxicillin (96.5% vs. 91%, p = 0.007) was
slightly higher in the ﬁrst period.
Conclusions: Although a reduction in infections due to vaccine serotypes was observed, close to half of
infections in adult patients were caused by PCV-13 serotypes. Even after pediatric vaccination with PCV-
13, vaccine serotypes were still responsible for most pneumonia and invasive disease, underscoring the
importance of implementing current guidelines and extending vaccination to other risk groups.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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Streptococcus pneumoniae causes upper and lower respiratory
tract infections, chronic obstructive pulmonary disease (COPD)
exacerbations, and community-acquired pneumonia, as well as
producing invasive disease.1 S. pneumoniae disease is responsible
for a high proportion of morbidity and mortality around the
world, mainly in young children and elderly patients.2,3
Pneumococcal disease is the disease with an available vaccine
with the highest mortality rate.3 In early 2000, a 7-valent* Corresponding author. Tel.: +34-871202035; fax: +34-871202352.
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/4.0/).pneumococcal conjugate vaccine (PCV-7) was licensed in the USA
for use in all infants and children under 2 years of age and in high-
risk children aged 2–4 years.4 Following the authorization of PCV-
7, distribution of the vaccine through public programs began and
a decline in the rate of pneumococcal disease was observed, not
only in children, but also among adults, as well as a reduction in
the incidence of antibiotic resistance.4–7 As PCV-7 included
polysaccharides of serotypes 4, 6B, 9 V, 14, 18C, 19F, and 23F,
most of the 90 pneumococcal serotypes were not covered by this
vaccine, so an increase in infections due to some non-PCV-7
serotypes was observed, mainly serotypes 1, 3, 7F, and 19A.
Moreover, there was also some concern regarding the increase in
severity in some cases of pneumococcal disease, since some of
these serotypes are more aggressive.8–13ciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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was licensed by the US Food and Drug Administration (FDA) and
recommended by the Advisory Committee on Immunization
Practices (ACIP) for children aged 6 weeks through 71 months
for the prevention of invasive pneumococcal disease (IPD) caused
by the 13 pneumococcal serotypes included in the vaccine. In
addition to the seven serotypes of PCV-7, the new vaccine contains
polysaccharides of serotypes 1, 3, 5, 6A, 7F, and 19A. In Spain, PCV-
13 has been available since June 2010 and vaccination is
recommended for pediatric patients. However, in most provinces
of Spain the vaccine is not ﬁnanced by public health insurance, so it
has to be ﬁnanced by the parents. Although vaccine coverage for
children is not universal, a decline of around 55% in the number of
hospitalizations for IPD has been observed in Spain in children
aged <15 years,14 with a reduction in frequency of infections due
to vaccine serotypes, mainly 19A and 1, and severe clinical forms
such as complicated pneumonia with bacteremia, pleural effusion,
and/or meningitis.15–17 These changes have also been observed in
other settings.18,19
Because of the limited data currently available on the impact of
pediatric vaccination in other age groups, and since PCV-13 has
been authorized for adult patients at risk of pneumococcal disease,
it is important to ascertain the evolution of the different
pneumococcal serotypes, their role in different clinical situations,
and potential changes in severity of clinical presentation. The aim
of this study was to describe the pneumococcal serotype
distribution in adult patients in clinical practice since the
introduction of PCV-13, the role of vaccine and non-vaccine
serotypes in different clinical scenarios, and the severity and
outcomes of pneumococcal infections over a 4-year period.
2. Materials and methods
2.1. Patients and study design
This was a prospective study conducted in Hospital Son Lla`tzer,
a teaching center with 400 beds covering a population of
225 000 inhabitants in Mallorca (Spain). All pneumococcal
infection episodes from January 1, 2010 to April 30, 2014 were
collected. A person with signs and symptoms of infection,
respiratory or not, from whom S. pneumoniae was isolated was
deﬁned as having a pneumococcal infection. The quality of sputum
was assessed using the Murray and Washington criteria20 and
quantitative colony counts were used for bronchoscopy samples. S.
pneumoniae isolation in predominant culture from middle ear and
sinus aspirates or conjunctival swabs was considered positive, as
well as culture from blood or samples from pleural, cerebrospinal,
or synovial ﬂuid. The study was approved by the Research
Commission of Hospital Son Lla`tzer.
2.2. Clinical assessment and follow-up
All data were assessed by interview with the patients or their
relatives and a review of hospital health records. Data were
collected during and after the hospital stay once the Laboratory of
Microbiology reported the isolation of S. pneumoniae from at
least one of the referred samples. Data were recorded using a
standardized, computer-assisted protocol. The following data
were collected: demographic characteristics, substance use
habits, receipt of pneumococcal or inﬂuenza vaccine, comorbid-
ities, origin of the infection, clinical diagnosis, pneumococcal
serotype, antibiotic susceptibility, and outcomes, including
overall and infection-related hospital mortality. For time
calculations, the day of admission was considered to be hospital
day 0.2.3. Deﬁnitions
Patients were considered active smokers, alcohol or drug users
if the last consumption had occurred during the last year.
Comorbidities were assessed with the Charlson comorbidity index.
Patients were considered to be vaccinated against pneumococcus if
the 23-valent polysaccharide pneumococcal vaccine, PCV-7, or
PCV-13 had been administered in the 5 years before admission.
They were considered to be vaccinated against inﬂuenza if the
seasonal inﬂuenza vaccine had been administered during the year
prior to admission. The infection was considered healthcare-
associated or hospital-acquired according to accepted criteria.21
Clinical diagnoses included the following: (1) Pneumonia, deﬁned
in the presence of compatible signs and symptoms and a new
inﬁltrate on chest radiography. (2) COPD exacerbation or infected
bronchiectasis, diagnosed depending on whether a previous or
current diagnosis of COPD or bronchiectasis had been made, and in
the presence of at least two of the following: fever, increased
dyspnea, cough, and changes in volume or characteristics of
sputum. In the absence of a diagnosis of COPD or bronchiectasis,
the episode was categorized as lower respiratory tract infection.
(3) Otitis, sinusitis, and bacterial conjunctivitis, deﬁned in the
presence of compatible clinical signs and symptoms and with a
predominant culture of S. pneumoniae from middle ear or sinus
aspirates and conjunctival swabs. (4) IPD, diagnosed when blood or
cultures from samples of pleural, cerebrospinal, or synovial ﬂuid
were positive for S. pneumoniae.
The Fine score22 was calculated for community-acquired or
healthcare-associated pneumonia. Complications were deﬁned as
any untoward circumstances occurring during hospitalization.
Overall mortality was deﬁned as death from any cause during
hospitalization; related mortality was evaluated according to the
criteria of the research team. Hospital and intensive care unit (ICU)
admission and treatment decisions were not standardized and
were made by the attending physician.
2.4. Microbiological studies
Investigation of S. pneumoniae in each sample was performed
using standard microbiological procedures. The identiﬁcation of S.
pneumoniae was performed by observation on blood agar plates of
alpha-hemolytic colonies that were catalase-negative, optochin-
sensitive, and bile-soluble. In the case of uncertainty, an
agglutination probe with latex particles coated with speciﬁc
antiserum was used (Slidex Pneumo-kit; bioMe´rieux, Marcy
l’Etoile, France).
Susceptibility to penicillin, amoxicillin, and cefotaxime was
determined by Etest (AB Biodisk, Solna, Sweden) using cut-offs for
non-meningeal and meningeal isolates when indicated. Suscepti-
bility to erythromycin, tetracycline, trimethoprim–sulfamethoxa-
zole, and levoﬂoxacin was determined by disk plate (Oxoid) using
the 2010 Clinical and Laboratory Standards Institute criteria.23 For
serotyping, pneumococcal isolates were sent to the Pneumococcal
Reference Laboratory, Centro Nacional de Microbiologı´a, Instituto
de Salud Carlos III (Madrid, Spain).
2.5. Statistical analysis
Data were analyzed using a commercially available statistical
software package (SPSS 15.0; SPSS Inc., Chicago, IL, USA).
Descriptive statistics were generated for all study variables. The
analysis was conducted for all patients with a documented
pneumococcal infection, and also after excluding those with an
unknown serotype. A comparative analysis between those with a
known serotype and those with an unknown serotype was carried
out to check homogeneity of the two populations. Patients aged
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were calculated as percentages of patients with available data.
For the comparative analysis, two periods of time were
considered: (1) the ﬁrst period included the months immediately
pre and post PCV-13 authorization in Spain (January 1, 2010 to
December 31, 2011), and (2) the second period was from January 1,
2012 to April 30, 2014.
Descriptive and comparative analyses were performed for the
distribution of serotypes in different clinical scenarios, disease
severity, mortality, and antibiotic susceptibility in the two periods.
All isolates with a susceptibility test available were analyzed, even if
the serotype was unknown. Intermediate-susceptible and resistant
isolates were categorized as having reduced susceptibility.
The Chi-square test or Fisher’s exact test was used for
comparisons of categorical variables, and the corresponding odds
ratio (OR) with 95% conﬁdence interval (95% CI) was calculated.
The Student’s t-test was applied for continuous variables.
Statistical signiﬁcance was established at a = 0.05. All reported
p-values are two-tailed.
3. Results
3.1. Population characteristics
During the study, 562 pneumococcal infections were diagnosed
in 506 patients; 396 episodes (70.5%) were in men. The median
patient age was 68 (range 0–99) years. The serotype was obtained
in 414 (73.7%) cases and no clinical differences were observed
between cases with known serotypes and those with unknown
serotypes. After excluding seven pediatric patients, the ﬁnal
analysis was carried out for 407 episodes in 371 patients, 201 in the
ﬁrst period and 206 in the second. The epidemiological and clinical
characteristics of these episodes are detailed in Table 1.
3.2. Serotype distribution
During the ﬁrst period, 120 (59.7%) isolates were PCV-13
serotypes compared to 98 (47.6%) in the second period (OR 0.61,Table 1
General characteristics of the study population in each period
Variable First period Second period Signiﬁcance
n = 201 (%) n = 206 (%)
Male 148 (73.6) 136 (66) NS
Age, years, median (range) 69 (15–94) 68 (20–99) NS
Spanish origin 193 (96%) 195 (94.7%) NS
Smoker 60 (34.8) 62 (30.1) NS
Alcoholism 15 (7.5) 21 (10.2) NS
Intravenous drug use 5 (2.5) 6 (2.9) NS
Pneumococcal vaccine 7 (3.5) 13 (6.3) NS
Inﬂuenza vaccine 9 (4.5) 16 (7.8) NS
Community-acquired 126 (62.7) 111 (53.9) NS
Healthcare-acquired 75 (37.3) 95 (46.1) NS
Source of infection
Pneumonia 110 (54.7) 103 (50) NS
COPD 41 (20.4) 56 (27.2) NS
Tracheo-bronchitis 28 (13.9) 13 (6.3) NS
Bronchiectasis 10 (5) 7 (3.4) NS
ORL/ophthalmica 4 (1.9) 9 (4.4) NS
Otherb 8 (3.9) 18 (8.7) NS
Invasive infection 51 (25.4) 66 (32) NS
Charlson index (range) 2 (0–13) 2 (0–11) NS
Chronic lung disease 113 (56.2) 114 (55.3) NS
HIV-infected 13 (6.5) 15 (7.3) NS
NS, not signiﬁcant; COPD, chronic obstructive pulmonary disease; ORL, Otorhino-
laryngologic.
a Including otitis, sinusitis, and bacterial conjunctivitis.
b Primary bacteremia (3 vs. 7), meningitis (2 vs. 4), septic arthritis (1 vs. 1),
primary peritonitis (0 vs. 4), and abscesses (2 vs. 2).95% CI 0.41–0.90, p = 0.01) (Figure 1). The frequency of isolated
serotypes in both periods – those included in PCV-7, the additional
ones in PCV-13, and those not included in conjugate vaccines – are
summarized in Table 2. Serotypes 1, 5, and 9 V were not observed
in either time period.
There were four cases of meningitis in each period and a
serotype could be obtained for six of them: two in the ﬁrst period
(serotypes 3 and 6B) and four in the second period, two were PCV-
13 serotypes (3 and 19A) and two were additional serotypes not
included in PCV-13 (22F and 23B).
3.3. Severity and mortality
During the ﬁrst and second periods, 178 (88.6%) and 180 (87.4%)
patients, respectively, were hospitalized; 23 (12.8%) and 24
(13.3%), respectively, needed ICU admission. One hundred and
ninety cases of pneumonia (ﬁrst period 103 and second period 87)
were evaluated for severity; no differences were observed in the
Fine score: 98.5 (standard deviation 33.9) vs. 94.5 (standard
deviation 33.4) points. In the second period, more patients met the
criteria for severe sepsis and needed non-invasive ventilation, but
no differences were observed for other complications or mortality
(Table 3).
In the second period, PCV-13 serotypes were still a frequent
cause of pneumonia (57, 58.2%) and IPD (40, 40.8%), but these
serotypes were not related to septic shock and other outcome
variables. In the ﬁrst period, 22 of 41 cases (53.6%) of COPD
exacerbation were due to non-vaccine serotypes; there was a
tendency for this to increase in the second period, 34 of 56 cases
(60.7%), although this did not reach statistical signiﬁcance.
3.4. Antibiotic susceptibility
During the ﬁrst period, higher rates of susceptibility to
penicillin and amoxicillin were observed, but rates of susceptibility
to other antibiotics were similar (Table 4). No differences were
observed between the two periods regarding rates of susceptibility
to different tested antibiotics when the serotypes most frequently
isolated for each period (3, 11A, 14, 19A, and 19F) were analyzed
individually.
4. Discussion
In the present work we studied a signiﬁcant number of
pneumococcal infections in adult patients during two periods of
time, one before and the other after PCV-13 was authorized for use
in children in Spain. A proportional decrease in vaccine serotype
cases was observed. Although clinical and epidemiological
characteristics of the patients with pneumococcal infections did
not change throughout the study, a shift in proportion of the
different pneumococcal serotypes was observed, with a 12%
decrease in the additional serotypes included in PCV-13. Given the
low rate of pneumococcal vaccination in adult patients at risk, this
effect could be attributed to herd immunity related to vaccination
of the pediatric population, although nearly 50% of the isolates in
the second period were still PCV-13 serotypes. Moreover, in the
second period, PCV-13 serotypes were still responsible for more
than half of the cases of pneumonia and 40% of IPD, underscoring
the importance of implementing current guidelines and extending
pneumococcal vaccination to other groups at risk24,25 (as were
most of our patients) in order to reduce the incidence and
complications of pneumococcal infections. A low rate of pneumo-
coccal vaccination of patients at risk has been reported previously,
with some concern regarding the usefulness of polysaccharide
pneumococcal vaccine.26–28 Although more studies are needed to
demonstrate the efﬁcacy of PCV-13 for these patients, ﬁndings of
Figure 1. Proportional evolution of pneumococcal serotypes isolated during the study period. Isolates of serotypes not included in conjugate vaccines increased in the second
period, serotypes included in PCV-7 remained stable, and additional ones in PCV-13 decreased (OR 0.61, 95% CI 0.41–0.90, p = 0.01).
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advantages such as immunological memory and activity in
nasopharyngeal colonization are hopeful.29 Nevertheless, the
predominance of non-vaccine serotypes in COPD exacerbations
in both periods in our setting could limit the possible beneﬁt of
vaccinating this group.
As expected, PCV-7 serotypes did not change substantially
between the two periods, because vaccination against those
serotypes has been stable since early 2000. A decrease for the six
additional PCV-13 serotypes would be expected, but surprisingly
not all of the PCV-13 serotypes followed the same evolution
between the ﬁrst and second period: serotypes 3 and 7F decreased,
while serotypes 6A and 19A remained stable. Nevertheless, a
decrease in infections due to serotype 19A has been described in
children following PCV-13 vaccination.15–19 Our results are
difﬁcult to compare with those of other studies because published
data on changes in the prevalence of the different pneumococcal
serotypes in adults after the introduction of PCV-13 are still scarce.
However, our data do not override the substantial decrease in the
two serotypes that decrease the most. No isolation of serotypes 1,
5, and 9V was observed, perhaps because only adult patients were
included.30
In general, the severity of all infections did not increase
throughout the study, and the severity of pneumonia and IPD, in
particular, was similar in the two periods, although a signiﬁcant
percentage of episodes in the second period were caused by PCV-
13 serotypes. This circumstance could be related to the relative
decrease in frequency of additional serotypes included in PCV-13
with respect to PCV-7, and may be the result of some kind of herd
immunity related to pediatric vaccination. The increase in cases of
severe sepsis during the second period is probably related to the
implementation of a protocol for the early detection of sepsis in our
institution, increasing the sensitivity for classifying an infection assevere sepsis. Non-invasive ventilation is an intervention that has
increased for ICU and non-ICU patients in our center during recent
years, so an increase in the frequency of its use could be expected in
the second period. In addition, the observed statistical difference
must be considered with caution due to the small sample size of
patients in whom that procedure was used in this series. Neither
other complications nor mortality changed substantially through-
out the study.
The rates of isolates non-susceptible to penicillin or amoxicillin
were low, although they were higher in the second period. After
the introduction of PCV-7, a decrease in non-susceptibility to
penicillin and third-generation cephalosporins or macrolides was
observed.31,32 In recent years this trend has reversed, with a
rebound in resistance due to an increase in infections caused by
serotypes not included in PCV-7, such as 19A, 15A, and 35B.33,34 In
a Spanish study, serotypes 19A, 14, 24F, and 9V were found to be
responsible for 66% of penicillin non-susceptible isolates.35 This
trend has been corroborated in other studies, with a 2.5 times
greater risk of IPD for non-susceptible strains.36–38 In our study, the
isolation of serotype 19A did not change with time, whereas
infections with other non-vaccine serotypes less susceptible to
beta-lactams – 15A, 35B, and 24F – increased, which may explain
the trends observed.
Since this study was conducted in a single center in a limited
geographic area, it is not necessarily representative of the situation
in Spain. Because of a lack of ﬁnancing for PCV-13 by the Spanish
public health insurance, we only have an estimation of the data
regarding vaccine coverage in the pediatric population. According
to data supplied by the Regional Ministry of Health (Conselleria de
Salut, Govern Balear), rates of pediatric vaccination ranged from
23.4% in 2010 to 26.1% in 2013. These are probably below the real
rates, as the data are based on reports from public and also private
pediatricians; in the latter case, a percentage of underreporting
Table 2
Frequency of isolated serotypes in both periods
Isolated serotypes First period Second period
n = 201 (%) n = 206 (%)
Included in PCV-7 37 (18.4) 37 (18)
4 4 (2) 4 (1.9)
6B 4 (2) 10 (4.9)
9V 0 (-) 0 (-)
14 9 (4.5) 13 (6.3)
18C 2 (1) 0 (-)
19F 12 (6) 8 (3.9)
23F 6 (3) 2 (1)
Included in PCV-13 (additional) 83 (41.3) 61 (29.6)
1 0 (-) 0 (-)
3 35 (17.4) 23 (11.2)
5 0 (-) 0 (-)
6A 7 (3.5) 7 (3.4)
7F 18 (9) 8 (3.9)
19A 23 (11.4) 23 (11.2)
Not included in conjugate vaccines 81 (40.3) 108 (52.4)
6C 11 (5.5) 7 (3.4)
8 0 (-) 3 (1.5)
10A 3 (1.5) 2 (1)
11A 10 (5) 22 (10.7)
11C 0 (-) 1 (0.5)
11D 1 (0.5) 0 (-)
11F 1 (0.5) 0 (-)
12F 2 (1) 3 (1.5)
13 0 (-) 1 (0.5)
15A 3 (1.5) 4 (1.9)
15B 1 (0.5) 6 (2.9)
15C 1 (0.5) 1 (0.5)
16F 4 (2) 3 (1.5)
17A 1 (0.5) 1 (0.5)
17F 2 (1) 1 (0.5)
20 2 (1) 0 (-)
21 0 (-) 1 (0.5)
22F 8 (4) 12 (5.8)
23A 9 (4.5) 8 (3.9)
23B 5 (2.5) 8 (3.9)
24F 1 (0.5) 2 (1)
29 2 (1) 1 (0.5)
31 5 (2.5) 4 (1.9)
33F 4 (2) 4 (1.9)
34 2 (1) 3 (1.5)
35B 0 (-) 6 (2.9)
35F 2 (1) 2 (1)
37 0 (-) 1 (0.5)
38 1 (0.5) 1 (0.5)
PCV, pneumococcal conjugate vaccine.
Table 4
Percentages of susceptibility to different tested antibiotics for all pneumococcal
isolates in both periods
Antibiotic First period
n = 284 (%)
Second period
n = 266 (%)
Signiﬁcance
OR (95% CI) p-value
Penicillin 98.2 95.1 2.87 (1.01–8.18) 0.03
Amoxicillin 96.5 91 2.71 (1.27–5.79) 0.007
Cefotaxime 95.4 93.3 NS
Erythromycin 73.9 70.7 NS
Tetracycline 84.1 79.8 NS
Trimethoprim–
sulfamethoxazole
73.4 70 NS
Vancomycin 100 100 NS
Levoﬂoxacin 96.5 96.3 NS
OR, odds ratio; CI, conﬁdence interval; NS, not signiﬁcant.
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Consumption (Ministerio de Salud y Consumo, Gobierno de
Espan˜a) estimated that conjugate pneumococcal vaccine coverage
for children under 2 years of age was less than 50%.39
No serotype was recorded for over 20% of episodes, although
there were no substantial differences between these cases andTable 3
Main complications and mortality of pneumococcal infection in each period
Variable First period
n = 178 (%)
Second period
n = 180 (%)
Signiﬁcance
OR (95% CI) p-value
Bacteremia 49 (41.2%) 60 (52.2%) NS
Pleural effusion 9 (5) 5 (2.8) NS
Empyema 2 (1.1) 3 (1.7) NS
Severe sepsis 16 (8.9) 36 (20) 2.66 (1.41–5.03)
0.002
Septic shock 14 (7.9) 18 (10) NS
Non-invasive ventilation 1 (0.6) 8 (4.4) 8.51 (1.05–68.81)
0.01
Invasive ventilation 15 (8.4) 9 (5) NS
Overall mortality 11 (6.2%) 14 (7.7%) NS
Related mortality 10 (5.6%) 10 (5.5%) NS
OR, odds ratio; CI, conﬁdence interval; NS, not signiﬁcant.those with known serotypes. In other studies, the percentages of
serotyped isolates have been even lower.40 Finally, the sample size
for some comparisons was too small to establish a deﬁnite
association.
Regarding the strengths, a single-center study beneﬁts from the
exhaustive collection of clinical and outcome characteristics and
uniformity of clinical management and hospital and ICU admission
criteria. Unlike other studies focusing only on IPD, we also
considered isolates from non-invasive infections, such as non-
bacteremic pneumonia and COPD exacerbation. The low polysac-
charide pneumococcal vaccination rates observed prevents the
interference of adult vaccination. With current pneumococcal
vaccine recommendations, a signiﬁcant proportion of patients
studied here will be vaccinated with PCV-13 in the near future,
making it difﬁcult to reproduce this study. However, as vaccination
rates increase, it will be interesting to follow this population in
order to explore whether the proportions of serotypes continue to
change in vaccinated versus unvaccinated subjects.
In conclusion, although a 12% reduction in disease caused by the
new serotypes included in the PCV-13 vaccine has been observed
since 2010, following authorization for the use of this vaccine in
children, nearly half of infections in adult patients are still caused
by vaccine serotypes. Not all vaccine serotypes responded in the
same way. Even after pediatric vaccination with PCV-13, vaccine
serotypes are still responsible for most pneumonia and IPD,
underscoring the importance of implementing current guidelines
and extending vaccination to other groups at risk of pneumococcal
infection.
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